XBIT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by XBiotech Inc.
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into XBiotech Inc. for potential securities fraud violations. This follows XBiotech's announcement of pausing a phase 2 rheumatoid arthritis program due to the failure of its candidate, Natrunix, to meet primary endpoints.
December 27, 2024 | 10:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
XBiotech Inc. is under investigation for potential securities fraud after its rheumatoid arthritis drug, Natrunix, failed in phase 2 trials, leading to a program pause.
The investigation into potential securities fraud and the failure of Natrunix in phase 2 trials are likely to negatively impact XBiotech's stock price. The legal implications and halted drug development could undermine investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100